South Korea · Delayed Price · Currency is KRW BCWORLD PHARM. Statistics
Total Valuation
BCWORLD PHARM. has a market cap or net worth of KRW 38.82 billion. The enterprise value is 119.64 billion.
| Market Cap | 38.82B |
| Enterprise Value | 119.64B |
Important Dates
The next estimated earnings date is Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
BCWORLD PHARM. has 8.44 million shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | 8.44M |
| Shares Outstanding | 8.44M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 47.31% |
| Owned by Institutions (%) | n/a |
| Float | 4.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.52 |
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.55 |
| P/FCF Ratio | 9.18 |
| P/OCF Ratio | 5.86 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.66, with an EV/FCF ratio of 28.29.
| EV / Earnings | -31.97 |
| EV / Sales | 1.59 |
| EV / EBITDA | 10.66 |
| EV / EBIT | 34.90 |
| EV / FCF | 28.29 |
Financial Position
The company has a current ratio of 0.50, with a Debt / Equity ratio of 1.18.
| Current Ratio | 0.50 |
| Quick Ratio | 0.27 |
| Debt / Equity | 1.18 |
| Debt / EBITDA | 7.70 |
| Debt / FCF | 20.43 |
| Interest Coverage | 0.77 |
Financial Efficiency
Return on equity (ROE) is -2.72% and return on invested capital (ROIC) is 1.32%.
| Return on Equity (ROE) | -2.72% |
| Return on Assets (ROA) | 1.22% |
| Return on Invested Capital (ROIC) | 1.32% |
| Return on Capital Employed (ROCE) | 4.11% |
| Revenue Per Employee | 268.99M |
| Profits Per Employee | -13.37M |
| Employee Count | 280 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.43 |
Taxes
In the past 12 months, BCWORLD PHARM. has paid 446.83 million in taxes.
| Income Tax | 446.83M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.86% in the last 52 weeks. The beta is 0.85, so BCWORLD PHARM.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | +3.86% |
| 50-Day Moving Average | 4,509.70 |
| 200-Day Moving Average | 4,579.13 |
| Relative Strength Index (RSI) | 43.21 |
| Average Volume (20 Days) | 11,733 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BCWORLD PHARM. had revenue of KRW 75.32 billion and -3.74 billion in losses. Loss per share was -403.09.
| Revenue | 75.32B |
| Gross Profit | 30.46B |
| Operating Income | 3.43B |
| Pretax Income | -1.59B |
| Net Income | -3.74B |
| EBITDA | 11.22B |
| EBIT | 3.43B |
| Loss Per Share | -403.09 |
Balance Sheet
The company has 5.63 billion in cash and 86.41 billion in debt, giving a net cash position of -80.77 billion or -9,572.06 per share.
| Cash & Cash Equivalents | 5.63B |
| Total Debt | 86.41B |
| Net Cash | -80.77B |
| Net Cash Per Share | -9,572.06 |
| Equity (Book Value) | 73.43B |
| Book Value Per Share | 8,695.43 |
| Working Capital | -46.04B |
Cash Flow
In the last 12 months, operating cash flow was 6.62 billion and capital expenditures -2.39 billion, giving a free cash flow of 4.23 billion.
| Operating Cash Flow | 6.62B |
| Capital Expenditures | -2.39B |
| Free Cash Flow | 4.23B |
| FCF Per Share | 501.14 |
Margins
Gross margin is 40.44%, with operating and profit margins of 4.55% and -4.97%.
| Gross Margin | 40.44% |
| Operating Margin | 4.55% |
| Pretax Margin | -2.11% |
| Profit Margin | -4.97% |
| EBITDA Margin | 14.90% |
| EBIT Margin | 4.55% |
| FCF Margin | 5.61% |
Dividends & Yields
This stock pays an annual dividend of 90.91, which amounts to a dividend yield of 1.96%.
| Dividend Per Share | 90.91 |
| Dividend Yield | 1.96% |
| Dividend Growth (YoY) | 10.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.03% |
| Shareholder Yield | 1.93% |
| Earnings Yield | -9.64% |
| FCF Yield | 10.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 27, 2024. It was a forward split with a ratio of 1.1.
| Last Split Date | Dec 27, 2024 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
BCWORLD PHARM. has an Altman Z-Score of 0.74 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.74 |
| Piotroski F-Score | 6 |